Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

MoonLake Immunotherapeutics (MLTX) Leases (2022 - 2026)

MoonLake Immunotherapeutics' Leases history spans 5 years, with the latest figure at $1.9 million for Q1 2026.

  • Quarterly Leases fell 28.27% to $1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Mar 2026, down 28.27% year-over-year, with the annual reading at $1.6 million for FY2025, 46.41% down from the prior year.
  • Leases came in at $1.9 million for Q1 2026, up from $1.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.7 million in Q1 2024 to a low of $169422.0 in Q3 2023.
  • The 5-year median for Leases is $2.1 million (2025), against an average of $2.0 million.
  • Year-over-year, Leases skyrocketed 1818.99% in 2024 and then plummeted 46.41% in 2025.
  • MoonLake Immunotherapeutics' Leases stood at $282580.0 in 2022, then soared by 1184.05% to $3.6 million in 2023, then dropped by 19.47% to $2.9 million in 2024, then tumbled by 46.41% to $1.6 million in 2025, then increased by 18.58% to $1.9 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Leases are $1.9 million (Q1 2026), $1.6 million (Q4 2025), and $1.9 million (Q3 2025).